Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
3期
已完成
NCT00365859
| 适应症 | Autistic Disorder, Behavioral Symptoms |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 330 人 |
|---|
| 干预（药物） | Aripiprazole |
|---|
| 开始日期 | 2006年9月1日 |
|---|
| 完成日期 | 2009年6月1日 |
|---|
| 结果公布日 | 2010年1月25日 |
|---|
摘要
This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]).
Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs
From Screening (up to 42 days prior to treatment start) through Week 52 (end of study) for SAEs; from Week 0 (Baseline) through Week 52 (End of Study) for AEs · Participants
| De Novo | 0 Participants |
|---|
| Rollover Placebo | 0 Participants |
|---|
| Rollover Aripiprazole | 0 Participants |
|---|
| Total | 0 Participants |
|---|
| De Novo | 3 Participants |
|---|
| Rollover Placebo | 1 Participants |
|---|
Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52
Baseline, Week 8, Week 26, Week 52 · units on a scale
| De Novo | 10.7 ± 1.40 units on a scale |
|---|
| Rollover Placebo | 10.6 ± 1.17 units on a scale |
|---|
| Rollover Aripiprazole | 11.0 ± 2.11 units on a scale |
|---|
| Total | 10.8 ± 1.77 units on a scale |
|---|
| De Novo | -0.3 ± 1.13 units on a scale |
|---|
| Rollover Placebo | 0.1 ± 1.51 units on a scale |
|---|
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52
Baseline, Week 8, Week 26, Week 52 · units on a scale
| De Novo | 0.5 ± 1.90 units on a scale |
|---|
| Rollover Placebo | 0.5 ± 1.02 units on a scale |
|---|
| Rollover Aripiprazole | 0.3 ± 1.23 units on a scale |
|---|
| Total | 0.4 ± 1.40 units on a scale |
|---|
| De Novo | -0.3 ± 1.45 units on a scale |
|---|
| Rollover Placebo | -0.1 ± 0.87 units on a scale |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。